| GB835638A (en) | 1956-12-01 | 1960-05-25 | Novo Terapeutisk Labor As | Insulin crystal suspensions having a protracted effect |
| GB840870A (en) | 1957-08-03 | 1960-07-13 | Novo Terapeutisk Labor As | Improvements in or relating to insulin preparations |
| JPS6033474B2 (en) | 1978-05-11 | 1985-08-02 | 藤沢薬品工業株式会社 | Novel hyaluronidase BMP-8231 and its production method |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| CA1275922C (en)* | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| DK257988D0 (en) | 1988-05-11 | 1988-05-11 | Novo Industri As | NEW PEPTIDES |
| DE3837825A1 (en) | 1988-11-08 | 1990-05-10 | Hoechst Ag | NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| DE69024953T3 (en) | 1989-05-04 | 2005-01-27 | Southern Research Institute, Birmingham | encapsulation |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| DK155690D0 (en) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | NEW PEPTIDES |
| US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| DK36392D0 (en) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | USE OF CHEMICAL COMPOUND |
| US5846747A (en) | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
| DK39892D0 (en) | 1992-03-25 | 1992-03-25 | Bernard Thorens | PEPTIDE |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| JP2837956B2 (en) | 1993-06-21 | 1998-12-16 | ノボ ノルディスク アクティーゼルスカブ | Asp ▲ B28 ▼ Insulin crystal |
| JPH09505308A (en) | 1993-11-19 | 1997-05-27 | アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー | Production of biodegradable microparticles containing biologically active agents |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| KR100600457B1 (en) | 1996-06-05 | 2006-07-13 | 로셰 디아그노스틱스 게엠베하 | Exendin analogs, preparation methods thereof, and pharmaceuticals containing the same |
| DE19637230A1 (en) | 1996-09-13 | 1998-03-19 | Boehringer Mannheim Gmbh | Exendin analogues, process for their preparation and medicaments containing them |
| EP0910402B1 (en)* | 1996-06-20 | 2007-08-08 | Novo Nordisk A/S | Insulin preparations containing mannitol |
| US5948751A (en)* | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| JP4404380B2 (en)* | 1996-06-20 | 2010-01-27 | ノボ ノルディスク アクティーゼルスカブ | NaCl-containing insulin preparation |
| US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
| ES2359031T3 (en) | 1996-08-08 | 2011-05-17 | Amylin Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN EXENDIN-4 PEPTIDE. |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
| AU739020B2 (en) | 1997-01-07 | 2001-10-04 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| WO1998035033A1 (en) | 1997-02-05 | 1998-08-13 | 1149336 Ontario Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
| US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
| ES2190087T3 (en) | 1997-06-13 | 2003-07-16 | Genentech Inc | STABILIZED FORMULATION OF AN ANTIBODY. |
| PE79099A1 (en) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | STABLE INSULIN FORMULATIONS |
| NZ502592A (en) | 1997-08-08 | 2002-03-28 | Amylin Pharmaceuticals Inc | Exendin agonist peptides and their use in the treatment of type I and II diabetes |
| ID24890A (en)* | 1997-10-24 | 2000-08-31 | Lilly Co Eli | INSULIN COMPOSITIONS THAT CANNOT BE SOLUTED |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| JP2003522721A (en) | 1997-11-14 | 2003-07-29 | アミリン・ファーマシューティカルズ，インコーポレイテッド | New exendin agonist compounds |
| ATE383867T1 (en) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | NOVEL EXENDIN AGONISTS |
| EP1049486A4 (en) | 1997-12-05 | 2006-01-04 | Lilly Co Eli | Glp-1 formulations |
| AU759058C (en) | 1998-02-13 | 2005-09-15 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| EP1950223A3 (en) | 1998-03-09 | 2009-05-13 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| ATE269103T1 (en) | 1998-03-13 | 2004-07-15 | Novo Nordisk As | STABILIZED AQUEOUS GLUCAGON SOLUTIONS CONTAINING DETERGENTS |
| JP2002516880A (en) | 1998-06-05 | 2002-06-11 | テクニオン リサーチ アンド デベロップメント ファウンデーション リミテッド | Insulin supplemented infant formula |
| EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| US6489292B1 (en) | 1998-11-18 | 2002-12-03 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
| JP2007204498A (en) | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | Long-term stabilized formulations |
| JP2000247903A (en) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | Long-term stabilized pharmaceutical preparation |
| US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
| WO2000066629A1 (en) | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6344180B1 (en) | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| DE19947456A1 (en) | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | New synthetic derivatives of the C-peptide of proinsulin, useful in the preparation of human insulin or insulin analogs in high yield |
| PL211886B1 (en) | 1999-10-04 | 2012-07-31 | Novartis Vaccines & Diagnostic | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| US20010012829A1 (en) | 2000-01-11 | 2001-08-09 | Keith Anderson | Transepithelial delivery GLP-1 derivatives |
| AU2353701A (en) | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| DE10114178A1 (en) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinc-free and low-zinc insulin preparations with improved stability |
| EP1377608B1 (en) | 2001-04-02 | 2009-09-16 | Novo Nordisk A/S | Insulin precursors and a process for their preparation |
| US7156877B2 (en) | 2001-06-29 | 2007-01-02 | The Regents Of The University Of California | Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs |
| JP2005508895A (en) | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Premix of GLP-1 and basal insulin |
| HUP0700126A2 (en) | 2001-12-20 | 2007-06-28 | Lilly Co Eli | Insulin molecule having protracted time action |
| AU2003203146A1 (en) | 2002-02-07 | 2003-09-02 | Novo Nordisk A/S | Use of glp-1 compound for treatment of critically ill patients |
| JP2005526126A (en) | 2002-05-07 | 2005-09-02 | ノボ ノルディスク アクティーゼルスカブ | Soluble preparation containing insulin aspart and insulin detemia |
| ATE496064T1 (en) | 2002-05-07 | 2011-02-15 | Novo Nordisk As | SOLUBLE FORMULATIONS CONTAINING MONOMERIC INSULIN AND ACYLATED INSULIN |
| DE10227232A1 (en) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Sour insulin preparations with improved stability |
| EP2028192A1 (en) | 2002-07-04 | 2009-02-25 | Zealand Pharma A/S | GLP-1 and methods for treating diabetes |
| KR20050083713A (en) | 2002-10-02 | 2005-08-26 | 질랜드 파마 에이/에스 | Stabilized exendin-4 compounds |
| MXPA05009565A (en) | 2003-03-11 | 2005-12-02 | Novo Nordisk As | Pharmaceutical preparations comprising acid-stabilised insulin. |
| DE10325567B4 (en) | 2003-06-05 | 2008-03-13 | Mavig Gmbh | Radiation protection arrangement with separable enclosure |
| EP1663295A2 (en) | 2003-09-01 | 2006-06-07 | Novo Nordisk A/S | Stable formulations of peptides |
| TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| ES2373660T3 (en) | 2003-11-13 | 2012-02-07 | Novo Nordisk A/S | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INSULINOTROPIC GLP-1 ANALOG (7-37), ASP INSULIN (B28) AND A TENSIOACTIVE. |
| US20050201978A1 (en) | 2003-11-17 | 2005-09-15 | Lipton James S. | Tumor and infectious disease therapeutic compositions |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| JP5000493B2 (en) | 2004-05-20 | 2012-08-15 | ディアメディカ インコーポレイテッド | Pharmaceutical composition for treating insulin resistance, method of using bethanechol and N-acetylcysteine in the preparation of said pharmaceutical composition and kit comprising said pharmaceutical composition |
| US20060073213A1 (en) | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
| US20080280814A1 (en) | 2004-09-17 | 2008-11-13 | Novo Nordisk A/S | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide |
| EP2494983B1 (en) | 2004-11-12 | 2019-04-24 | Novo Nordisk A/S | Stable formulations of glp-1 |
| ES2575984T3 (en) | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Stable formulations of peptides containing an acylated GLP-1 analogue and a basal insulin |
| WO2006053906A1 (en)* | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
| DE102004058306A1 (en) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Process for the preparation of carboxy-terminally amidated peptides |
| WO2006083952A2 (en) | 2005-02-01 | 2006-08-10 | Canberra Industries, Inc. | Maximum entropy signal detection method |
| ATE509634T1 (en) | 2005-04-08 | 2011-06-15 | Amylin Pharmaceuticals Inc | PHARMACEUTICAL FORMULATIONS CONTAINING INCRETIN PEPTIDE AND APROTIC-POLAR SOLVENT |
| EP1888118B1 (en) | 2005-05-25 | 2016-08-17 | Novo Nordisk A/S | Polypeptide formulations stabilized with ethylenediamine |
| WO2006131730A1 (en) | 2005-06-06 | 2006-12-14 | Camurus Ab | Glp-1 analogue formulations |
| DE102005046113A1 (en) | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Preparation of C-amidated peptides, useful as pharmaceuticals, by reaction between precursor peptides in presence of enzyme with activity of trypsin, also new reaction products |
| KR101105871B1 (en) | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | Stable Solution Formulation of Phosphorus Follicle Stimulating Hormone |
| EP1933884B1 (en) | 2005-10-11 | 2017-09-06 | Huntington Medical Research Institutes | Imaging agents and methods of use thereof |
| US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| WO2007082381A1 (en) | 2006-01-20 | 2007-07-26 | Diamedica Inc. | Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders |
| US20070191271A1 (en) | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
| EP1986674A4 (en) | 2006-02-13 | 2009-11-11 | Nektar Therapeutics | Methionine-containing protein or peptide compositions and methods of making and using |
| EP1996224B1 (en) | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
| WO2007113205A1 (en) | 2006-04-03 | 2007-10-11 | Novo Nordisk A/S | Glp-1 peptide agonists |
| EP2015769A4 (en) | 2006-04-13 | 2013-12-25 | Ipsen Pharma | Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
| DE102006031962A1 (en) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidated insulin glargine |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| DK2074141T3 (en) | 2006-09-22 | 2016-11-28 | Novo Nordisk As | The protease resistant insulin analogues. |
| WO2008124522A2 (en) | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
| MX2009011123A (en) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Suspension formulations of insulinotropic peptides and uses thereof. |
| CN101366692A (en) | 2007-08-15 | 2009-02-18 | 江苏豪森药业股份有限公司 | Stable Exenatide formulation |
| GB0717399D0 (en) | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| SI2219607T1 (en) | 2007-11-01 | 2012-09-28 | Merck Serono Sa | Liquid LH formulations |
| WO2009060071A1 (en)* | 2007-11-08 | 2009-05-14 | Novo Nordisk A/S | Insulin derivative |
| MX2010005245A (en) | 2007-11-16 | 2010-06-01 | Novo Nordisk As | Pharmaceutical compositions containing insulin and an insulinotropic peptide. |
| CN101444618B (en) | 2007-11-26 | 2012-06-13 | 杭州九源基因工程有限公司 | Pharmaceutical preparation containing exenatide |
| WO2009075859A2 (en) | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
| ES2613152T3 (en) | 2008-01-09 | 2017-05-22 | Sanofi-Aventis Deutschland Gmbh | New insulin derivatives with extremely delayed time / action profile |
| JP5695909B2 (en) | 2008-01-09 | 2015-04-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Novel insulin derivatives with extremely delayed time action profiles |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| TWI394580B (en) | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
| KR100928942B1 (en)* | 2008-05-26 | 2009-11-30 | 제이에스아이실리콘주식회사 | Process for producing straight or cyclic trisila alkanes |
| KR20110076918A (en) | 2008-09-10 | 2011-07-06 | 제넨테크, 인크. | Compositions and Methods for Preventing Oxidative Degradation of Proteins |
| CN101670096B (en) | 2008-09-11 | 2013-01-16 | 杭州九源基因工程有限公司 | Medicinal preparation containing exenatide |
| US20100092566A1 (en) | 2008-10-15 | 2010-04-15 | Alessi Thomas R | Highly concentrated drug particles, formulations, suspensions and uses thereof |
| CR20170369A (en) | 2008-10-17 | 2017-11-01 | Sanofi Aventis Deutschland | COMBINATION OF AN INSULIN AND A GLP-1 AGONIST (Divisional 2011-0188) |
| JP2009091363A (en) | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Stabilized aqueous injectable solution of pth |
| CN102596175A (en) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | Aqueous insulin preparations containing methionine |
| TW201113032A (en) | 2009-07-06 | 2011-04-16 | Sanofi Aventis Deutschland | Slow-acting insulin preparations |
| JP2012532177A (en) | 2009-07-06 | 2012-12-13 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Thermal and vibration stable insulin formulations |
| AU2010277560B2 (en) | 2009-07-31 | 2014-12-11 | Sanofi-Aventis Deutschland Gmbh | Long acting insulin composition |
| AR078161A1 (en) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD |
| WO2011058082A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| US20110118178A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| PL2498802T3 (en) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| EP2389945A1 (en) | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
| SG187904A1 (en) | 2010-08-30 | 2013-04-30 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| WO2012080320A1 (en) | 2010-12-14 | 2012-06-21 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
| KR20140041409A (en) | 2011-02-02 | 2014-04-04 | 사노피-아벤티스 도이칠란트 게엠베하 | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| US20120277147A1 (en) | 2011-03-29 | 2012-11-01 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| US20130040878A1 (en) | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
| US8735349B2 (en) | 2011-05-13 | 2014-05-27 | Sanofi-Aventis Deutschland Gmbh | Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L |
| JP6442284B2 (en) | 2011-05-13 | 2018-12-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Lixisenatide and metformin for the treatment of type 2 diabetes |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| EP2750699B1 (en) | 2011-08-29 | 2015-07-22 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| EP2763691A1 (en) | 2011-10-04 | 2014-08-13 | Sanofi-Aventis Deutschland GmbH | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract |
| SI2763690T1 (en) | 2011-10-04 | 2016-03-31 | Sanofi-Aventis Deutschland Gmbh | Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
| AU2012328388B2 (en) | 2011-10-28 | 2017-06-15 | Sanofi-Aventis Deutschland Gmbh | Treatment protocol of diabetes type 2 |
| US8901484B2 (en) | 2012-04-27 | 2014-12-02 | Sanofi-Aventis Deutschland Gmbh | Quantification of impurities for release testing of peptide products |
| AR092862A1 (en) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD |
| TWI641381B (en) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives |
| GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
| JP6641280B2 (en) | 2014-01-09 | 2020-02-05 | サノフイＳａｎｏｆｉ | Stabilized pharmaceutical formulations of insulin analogues and / or insulin derivatives |
| MX2016008977A (en)* | 2014-01-09 | 2016-10-04 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart. |
| CN105899191B (en) | 2014-01-09 | 2020-06-16 | 赛诺菲 | Stabilized glycerol-free pharmaceutical formulations of insulin analogues and/or insulin derivatives |